Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood – preliminary report

Kucia, Magda; Hałasa, Maciej; Wysoczynski, Marcin; Baśkiewicz-Masiuk, Magdalena; Moldenhawer, S; Zuba‐Surma, Ewa; Czajka, Ryszard; Wojakowski, Wojciech; Machalinski, Bogdan; Ratajczak, Mariusz Z.

doi:10.1038/sj.leu.2404470

Cited by 336 publications

(300 citation statements)

References 37 publications

Supporting

Mentioning

287

Contrasting

Unclassified

Order By: Relevance

“…In addition to HSCs, non-hematopoietic stem cell populations exist in CB, including, but not limited to, MSCs and more primitive stem cell populations with multi-lineage differentiation properties, that is, unrestricted somatic stem cells, multi-lineage progenitor cells, embryonic-like stem cells and very small embryonic-like stem cells that have respectively been shown to differentiate into neural cells. 14,17,[61][62][63][64][65] MSCs, which can also be isolated from BM and other sources, have been demonstrated to exert neuro-protection in HIE animal models. [66][67][68][69][70] Cell lines with NSC properties have been established from HUCB following immune-depletion of the CD34-positive cells from CB and spontaneous aggregation and differentiation with stimulation by epithelial growth factor.…”

Section: Cb Stem Cell Biologymentioning

confidence: 99%

Rescuing the neonatal brain from hypoxic injury with autologous cord blood

Liao

Cotten

Tan

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the risk of death or major neurological disabilities among neonates with HIE. However, in these trials, approximately 40% of cooled infants died or survived with significant impairments. Therefore, adjunct therapies are required to improve the outcome in neonates with HIE. Cord blood (CB) is a rich source of stem cells. Administration of human CB cells in animal models of HIE has generally resulted in improved outcomes and multiple mechanisms have been suggested including anti-inflammation, release of neurotrophic factors and stimulation of endogenous neurogenesis. Investigators at Duke are conducting studies of autologous CB infusion in neonates with HIE and in children with cerebral palsy. These pilot studies indicate no added risk from the regimens used, but results of ongoing placebo-controlled trials are needed to assess efficacy. Meanwhile, further investigations are warranted to determine the best strategies, that is, timing, dosing, route of delivery, choice of stem cells and ex vivo modulations, to attain long-term benefits of CB stem cell therapy.

show abstract

Section: Cb Stem Cell Biologymentioning

confidence: 99%

Rescuing the neonatal brain from hypoxic injury with autologous cord blood

Liao

Cotten

Tan

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…These cells were purified and demonstrated at the single cell level by using a novel two-step isolation procedure, i.e., removal of erythrocytes by hypotonic lysis combined with multiparameter FACS sorting ( Fig. 3B; Kucia et al, 2007). These CB-isolated VSEL (CB-VSEL) are very small (3-5 m) and highly enriched in a population of CXCR4 ϩ AC133 ϩ CD34 ϩ lin Ϫ CD45 Ϫ CB mononuclear cells, possess relatively large nuclei containing unorganized euchromatin, express nuclear embryonic transcription factors Oct-4 and Nanog and surface embryonic antigen SSEA-4.…”

Section: Oct-4 ؉ Stem Cells In Cord Bloodmentioning

confidence: 99%

Bone marrow‐derived very small embryonic‐like stem cells: Their developmental origin and biological significance

Kucia

Wan

Ratajczak

2007

Developmental Dynamics

View full text Add to dashboard Cite

Data from our and other laboratories provide evidence that bone marrow (BM) contains a population of stem cells that expresses early developmental markers such as (1) stage-specific embryonic antigen (SSEA) and (2) transcription factors Oct-4 and Nanog. These are the markers characteristic for embryonic stem cells, epiblast stem cells, and primordial germ cells (PGC). The presence of these stem cells in adult BM supports the concept that this organ contains some population of pluripotent stem cells that is deposited in embryogenesis during early gastrulation. We hypothesize that these cells could be direct descendants of the germ lineage that, to pass genes on to the next generations, has to create soma and, thus, becomes a "mother lineage" for all somatic cell lineages present in the adult body. Germ potential is established after conception in totipotent zygotes and retained in blastomeres of morula, cells from the inner cell mass of blastocyst, epiblast, and population of PGC. We will present a concept that SSEA ؉ Oct-4 ؉ Nanog ؉ cells identified in BM could be descendants of epiblast cells as well as some rare migrating astray PGC. Developmental Dynamics 236:3309 -3320, 2007.

show abstract

“…− from adult murine bone marrow [61] and CD133 + CD45 -LIN -from human umbilical cord blood [62]. TEM images showed a very primitive morphology with a large nuclei surrounded by a thin cytoplasmic ring, enriched in mitochondria [63].…”

Section: Very Small Embryonic/epiblast-like Stem Cellsmentioning

confidence: 99%

Cancer stem cells, their origin and niche: A search for the therapeutic target

Das¹,

Dutta²,

Paul³

et al. 2017

J Stem Cell Res Med

View full text Add to dashboard Cite

Cancer is a general term to define a group of genetic alterations and the subsequent phenotypic and physiological changes at the cellular level, leading to accelerated death of the host. According to The World Health Organisation (WHO), it is the second leading factor for human deaths globally. Cancer is such a difficult challenge for mankind because of its ability to relapse even after detailed treatments with chemotherapeutic agents and ionizing radiations. This can be explained by the emerging concept of 'tumor initiating cells' or 'cancer stem cells' (CSCs) which comprise a pluripotent and genomically dynamic subpopulation of the tumor microenvironment, occupying only 0.1%-3% of the total tumor population. Despite their emerging significance in disease progression and recurrence, the origin of these CSCs and their complex interaction with the corresponding CSC niche still remain to be elusive. In this review, we make an attempt to unwind the mystery of the origin of the CSCs as well as focus on the well-established cross-talk mechanisms between the CSCs and their niche components. Lastly, we try to find alternative therapeutic strategies to combat CSC resistance by targeting the various components of the CSC niche.

show abstract

Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood – preliminary report

Cited by 336 publications

References 37 publications

Rescuing the neonatal brain from hypoxic injury with autologous cord blood

Rescuing the neonatal brain from hypoxic injury with autologous cord blood

Bone marrow‐derived very small embryonic‐like stem cells: Their developmental origin and biological significance

Cancer stem cells, their origin and niche: A search for the therapeutic target

Contact Info

Product

Resources

About